Navigation Links
Takeda to Acquire Nycomed
Date:5/18/2011

#160;9.6 billion Euro inclusive of the Nycomed’s net debt(Fairness opinions from both Deutsche Securities Inc. and Nomura Securities Co., Ltd. have been obtained.)(6)

Planned date of completion: End of September 2011Note: Shares of Nycomed US Inc., which focuses on specialty pharmaceuticals in dermatology, are excluded from the share purchase agreement.3.  About Nycomed(1)

Corporate name: Nycomed A/S(2)

Headquarters: Zurich, Switzerland(3)

Representative: Hakan Bjorklund (CEO)(4)

Established: 2005 (Operation started in 1874)(5)

Capital stock: 98,836 Euro(6)

Shares: non-listed ordinary shares(7)

Fiscal year: End of December (8)

No. of employees: approximately 12,500 (including Nycomed US)(9)

Relationship with Takeda: no matters to report regarding capital, personal and transactional relationship with Takeda(10)

Financial performance of the Nycomed Group for the recent two yearsincluding Nycomed U.S. (unit: million Euro)Fiscal year 2010

Fiscal year 2009Net turnover

3,170.6

3,228.0Gross profit Margin

2,181.7

2,332.7Operating profit

-44.2

288.0Net profit

-229.1

232.7EBITDA after adjustment(*)

850.5

1,074.6Total assets

7,477

7,886Net assets

1,491

1,539(*) After adjustment of the difference such as those derived from evaluation of

inventories in accordance with "Accounting Standard for Business Combinations"

EBITDA: earnings before interest, taxes, depreciation, and amortizationTakeda will announce the financial impact which this transaction will have on its consolidated financial statements of its fiscal year 2011 together with the revised financial outlook of the year.

Takeda Media and Investor Contacts:
For Japanese Media and Global IR Inquiries:
Seizo Masuda
E-mail: masuda_seizo@takeda.co.jp
P
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... M. Bergman, Chairman and Chief Executive Officer of ... the largest provider of health care products and ... impact of a world without effective antibiotics before ... leaders of society at the World Economic Forum,s ...
... 2012  Vision-Sciences, Inc. (NASDAQ:  VSCI), a leading provider ... disposable EndoSheath® technology, today announced its participation at ... TIME: 2:30 PM EST ... "register/ watch event now" button. This ...
Cached Medicine Technology:Henry Schein's Chairman and CEO Addresses the World Economic Forum 2Henry Schein's Chairman and CEO Addresses the World Economic Forum 3Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd 2
(Date:5/21/2013)... Atlanta, GA (PRWEB) May 21, 2013 ... Care, ScripNet and Procura Management, today announced that ... Award at Catamaran’s client advisory meeting. Conferred ... has partnered with Catamaran to create cutting edge ... This year, Healthcare Solutions was recognized for its ...
(Date:5/21/2013)... May 21, 2013 Two-thirds of patients ... cell lung cancer reported that they engage in at ... use, according to new findings from the National ... Kantar Health . The research will be presented today ... Society for Pharmacoeconomics and Outcomes Research) in New Orleans. ...
(Date:5/21/2013)... 2013 A plastic surgery Internet ... plastic surgery SEO services following an Internet survey. ... name the “Best Plastic Surgery SEO Services”. , ... was predictable. Well-known in the plastic surgery Internet ... than any other selection based on superior client ...
(Date:5/21/2013)... May 21, 2013 It’s nearly summer and ... camp or starting practice for summer or fall sports. ... or sporting activities can begin. , To help parents ... for youth sports or camp physicals at just ... will review a child’s medical history, perform a physical exam ...
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives and ... Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate Casa ... facility serves meals and provides a social outlet for 45 ... Platinum Vice President, Mike Muench, says that the idea for ... “Platinum got its start selling long-term care insurance ,” ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3
... release is available in French . ... could be closer to reality, thanks to a discovery ... Hospital Research Centre. According to a study published in ... have become the first to clone, produce and purify ...
... patients with weakened immune systems. So it would seem ... prime breeding ground for infections because of the constantly ... whom could be exposed to bacteria and viruses at ... among the most common causes of illness and death ...
... Technology from Xiotech Selected by National Provider ... Minn., March 17 Xiotech Corporation today ... Emprise(TM) 7000 storage system, powered by Intelligent ... virtualization initiative. Milliman Care Guidelines will use ...
... 17 Siemens Energy & Automation, Inc. ... Mass., has selected Simatic(R) PCS 7 Lab ... manage pre- and post-clinical experimental data.(Logo: ... therapeutics based upon their novel polymeric nanoparticle ...
... (Hologic or the Company) (Nasdaq: HOLX ), ... medical imaging systems and surgical products dedicated to serving ... release its second quarter fiscal 2009 operating results on ... with the release, management will host a conference call ...
... Psychiatry , published by Elsevier, is very pleased to ... devoted to fundamental new insights into epigenetics, a field ... produce long-lasting or even heritable changes in gene function ... epigenetics in psychiatry promises several key advances, as noted ...
Cached Medicine News:Health News:Researchers clone key sperm-binding proteins 2Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 2Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 3Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 4Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 2Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 3Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 4Health News:BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S. 2Health News:BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S. 3Health News:Hologic to Release Second Quarter Fiscal 2009 Operating Results on Monday, May 4, 2009 2Health News:Understanding mental illness through gene-environment interactions 2
... long-life Active RFID tags using the wireless ... mobile assets or people, AeroScout enables the ... many different assets for the purpose of ... T2 Tag can be programmed via a ...
... Labels have a direct thermal print ... Tag-it™ HF-I transponder. When processed through ... and other graphics may be printed ... is programmed to the RFID transponder. ...
The PDC Smart® Key Fob can be programmed on demand using a 13.56 MHz RFID reader/writer and is ideal for long-term use applications such as electronic access control or loyalty programs....
... SURGICHIP™ is a patent pending solution ... embedded in a smart label to ... prevent wrong-patient, wrong-site, wrong-procedure surgery. This ... by an orthopedic surgeon with the ...
Medicine Products: